[Reaferon treatment in acute HBsAG-positive viral hepatitis].
Clinical, biochemical and serological examinations of 412 patients with acute HBsAg-positive virus hepatitis were conducted to assess therapeutic efficacy of Soviet recombinant alpha 2-interferon (reaferon). There were 309 cases of acute virus hepatitis B, 103 of delta infection (71--coinfection, 32--superinfection). The study and control groups were assigned randomly. Reaferon i.m. administration started on jaundice day 1-5 and lasted for 10-11 days. The treatment proved effective in acute hepatitis B running a moderately severe and severe course up to the development of acute hepatic encephalopathy. In delta infection reaferon produced response in coinfection only. In fulminant hepatitis the treatment was uneffective.
Gorbarets
I P
IP
Ketiladze
E S
ES
Farber
N A
NA
Bugaeva
N P
NP
Braginskiĭ
D M
DM
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D006509:Hepatitis B / Q000150:complications / Q000276:immunology / Q000628:therapy*; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D003699:Hepatitis D / Q000150:complications / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008875:Middle Aged; D011994:Recombinant Proteins
D006514:Hepatitis B Surface Antigens; D007370:Interferon Type I; D011994:Recombinant Proteins
Lechenie reaferonom ostrogo HBsAg-polozhitel'nogo virusnogo gepatita.